Pain Management Devices Market

The pain management devices market is worth USD 8,260.0 million in 2025 and reaches USD 18,375.0 million by 2035, compounding at 8.32% a year. The figure is built bottom-up: roughly 38.6 million pain management devices and procedure kits used globally in 2025, neurostimulation systems, infusion and analgesic pumps, ablation devices and other therapies, at a blended realised value of USD 214 per unit, triangulated against procedure volumes, implant registries and manufacturer disclosures. Volume grows 6.2% a year as non-opioid therapies spread, while realised value rises 2.0% a year as advanced neuromodulation and closed-loop systems take share.

What is the core judgment on pain devices?

Pain devices are the medical-technology answer to the opioid crisis, and payment policy has finally started to treat them that way. For two decades chronic and post-surgical pain were managed mostly with drugs, and the opioid epidemic showed the cost. Devices offer a non-addictive path: spinal cord stimulation for chronic back and nerve pain, peripheral nerve stimulation, radiofrequency ablation of pain-carrying nerves, and targeted infusion pumps. The obstacle was economics, because bundled hospital payments gave little reason to choose a more expensive non-opioid option. The United States NOPAIN Act changed that: from January 2025, Medicare pays separately for qualifying non-opioid pain treatments in hospital outpatient and ambulatory surgery settings, a direct incentive that favours devices and drugs that reduce opioid use. Technology is advancing at the same time, with closed-loop spinal cord stimulators that adjust therapy automatically, smaller rechargeable implants and wearable neuromodulation. The main risk is evidence and reimbursement scrutiny, since insurers question long-term outcomes for some implants. This report models the market unit by unit, and the exclusive chapter maintains the non-opioid reimbursement and therapy-adoption tracker.

What counts as pain management devices?

This study covers devices that treat pain: implanted and external neurostimulation (spinal cord, peripheral nerve, TENS), infusion and patient-controlled analgesia pumps, radiofrequency and cryo-ablation devices, and other devices such as wearable and thermal therapies, at manufacturer realised value. Pain drugs sit outside the boundary. The category sits within our medical devices coverage.

How is payment policy shifting care away from opioids?

Through the NOPAIN Act. Beginning January 2025, Medicare makes separate add-on payments for qualifying non-opioid pain treatments delivered in hospital outpatient departments and ambulatory surgery centers, removing the financial penalty that bundled payments placed on them. Hospitals and surgeons now have a reason to use nerve blocks, ablation and other non-opioid approaches after surgery. Separately, guidelines and state policies continue to limit opioid prescribing. The model carries this as a driver of procedure growth in the United States and a signal for other payers.

What drives demand?

The first driver is the shift from opioids: clinicians and payers seek non-addictive options for chronic and post-surgical pain. The second is aging and chronic disease: back pain, neuropathy and arthritis rise with age and diabetes. The third is technology: closed-loop and smaller rechargeable stimulators improve outcomes and patient acceptance. The fourth is outpatient migration: ablation and stimulation trials move to ambulatory settings, lowering cost and raising volumes.

What holds it back?

Three restraints are modelled: evidence and coverage scrutiny of long-term implant outcomes; high upfront costs and prior-authorisation hurdles; and complication and explant risks that temper adoption.

Which devices carry the value?

Neurostimulation leads with 44% of 2025 revenue, USD 3,634.4 million. Infusion and analgesic pumps hold 26%, USD 2,147.6 million, ablation devices 18%, USD 1,486.8 million, and other devices 12%, USD 991.2 million. Each category is modelled with unit and value tables through 2035.

Where are devices used?

North America leads with 48% of 2025 revenue, USD 3,964.8 million, growing 7.9% a year. Europe holds 24%, USD 1,982.4 million, at 7.4%, and Asia Pacific 18%, USD 1,486.8 million, compounding fastest at 10.2%. Latin America contributes USD 413.0 million, the Middle East USD 247.8 million, and Africa USD 165.2 million. Six regional models sum to the global figure.

Who supplies the devices?

Medtronic, Abbott and Boston Scientific lead neurostimulation, Nevro competes as a spinal cord stimulation specialist, and B. Braun and ICU Medical lead infusion and analgesic pumps. The competitive chapter profiles each player’s portfolio, evidence and reimbursement position.

How are pain devices priced?

Blended value averages USD 214 per unit in 2025, from low-cost TENS units and disposable kits to implanted stimulators costing tens of thousands of dollars. The pricing chapter publishes bands by device and region.

How do the scenarios look to 2035?

The base case carries 6.2% volume growth and 2.0% value growth for an 8.32% revenue CAGR and USD 18,375.0 million in 2035. The weak scenario trims the legs to 5.0% and 1.2%, landing near USD 15,200 million; the strong scenario lifts them to 7.1% and 2.6%, carrying the market past USD 21,200 million. Each 1-point change in volume growth moves the 2035 figure by roughly USD 1,700 million.

Which rules matter?

Device approval and post-market surveillance rules, the NOPAIN Act and other payment policies, and opioid-prescribing guidelines. The regulatory chapter maps these by market.

How does spinal cord stimulation work?

Spinal cord stimulation works by placing thin electrode leads in the epidural space near the spinal cord and delivering mild electrical pulses that interfere with pain signals travelling to the brain. Patients first undergo a trial in which temporary leads are connected to an external generator for several days; if pain falls substantially, a permanent system with an implanted pulse generator is placed under the skin, usually in the buttock or abdomen. Early systems produced a tingling sensation called paraesthesia that masked pain; newer approaches use high-frequency or burst waveforms that provide relief without that sensation, and closed-loop systems measure the spinal cord’s response to each pulse and adjust stimulation automatically as the patient moves. Batteries are rechargeable or primary cell, and modern devices are conditionally safe for magnetic resonance imaging. The main indications are persistent pain after spine surgery, complex regional pain syndrome, painful diabetic neuropathy and refractory back and leg pain. For this market, spinal cord stimulation carries the highest value per patient of any pain device, which is why it dominates neurostimulation revenue.

Why is the evidence debate so important?

The evidence debate matters because payers decide coverage on it, and the literature on implanted pain devices is genuinely mixed. Manufacturer-sponsored trials have reported substantial pain reductions for high-frequency and closed-loop stimulation, while some independent randomised trials and systematic reviews have found smaller or non-durable benefits, and critics point to placebo effects and short follow-up. Several insurers have tightened prior authorisation, and health technology bodies in Europe have questioned cost-effectiveness for certain indications. Manufacturers have responded with longer-term data, registries and trials in new indications such as painful diabetic neuropathy, where results have been stronger. The practical effect is that coverage varies by payer and country, and adoption depends on the strength of evidence for each indication. The model reflects this by growing established indications steadily and treating new indications as upside contingent on trial results and coverage decisions.

What role does radiofrequency ablation play?

Radiofrequency ablation treats pain by heating a small nerve with a needle electrode so that it stops transmitting pain signals, typically providing relief for six to twelve months until the nerve regenerates and the procedure is repeated. It is widely used for facet joint pain in the back and neck, sacroiliac joint pain and knee pain, and it is performed in outpatient settings under imaging guidance. Because it is minimally invasive, does not implant hardware and costs far less than a stimulator, it is often tried before implanted therapies, and it is a common alternative to long-term opioid use. Cooled radiofrequency systems treat larger areas, and cryoablation, which freezes rather than heats nerves, offers a similar approach. For manufacturers, ablation generates recurring revenue from disposable probes and kits rather than from expensive implants, and procedure volumes grow with outpatient capacity. The model grows ablation with procedure volumes in ambulatory settings.

Where does peripheral nerve stimulation fit?

Peripheral nerve stimulation places electrodes next to a specific nerve outside the spinal cord to treat localised pain, such as shoulder, knee, foot or post-surgical pain. Recent systems use small leads placed through a needle and either a temporary sixty-day treatment with an external generator or a permanently implanted micro-stimulator, and they avoid spinal surgery. The temporary approach is attractive because it can produce lasting relief after the device is removed, and it fits well into ambulatory practice. Reimbursement has improved in the United States, and use has grown quickly from a small base, including for post-operative pain as an alternative to opioids. The model treats peripheral nerve stimulation as the fastest-growing neurostimulation sub-segment, though from a much smaller base than spinal cord stimulation.

What are intrathecal pumps used for?

Intrathecal drug delivery pumps are implanted devices that deliver pain medication directly into the fluid around the spinal cord, allowing far smaller doses than oral or intravenous administration and reducing systemic side effects. They are used mainly for severe cancer pain and for selected patients with chronic non-cancer pain or severe spasticity, and they require refilling by a clinician every few months. Because the doses are small and targeted, they can reduce systemic opioid exposure substantially, which aligns with efforts to limit opioid use, although the therapy itself often delivers opioids. Adoption is limited by the need for specialist centres, refill logistics and careful patient selection, and safety incidents have prompted stricter protocols. The model grows intrathecal pumps slowly and treats them as a specialist segment within infusion and analgesic pumps.

How do wearables and simple devices compete?

Wearable and non-invasive devices compete at the low end of the market by offering drug-free relief without a procedure. Transcutaneous electrical nerve stimulation units, sold both by prescription and over the counter, deliver electrical pulses through skin electrodes; other devices use heat, cold, vibration or low-level laser. Newer wearable neuromodulation products target migraine, arthritis and post-surgical pain, and some connect to smartphone apps that adjust therapy and track use. Evidence for these devices varies, and many are sold direct to consumers rather than reimbursed. They matter to this market because they are high-volume, low-price products that expand the number of patients using device-based pain therapy and can lead patients toward clinical treatments if simple devices are insufficient. The model counts them within other devices and grows them with consumer demand rather than reimbursement.

How does reimbursement shape which therapy a patient receives?

Reimbursement shapes therapy because most pain treatments are expensive and few patients pay out of pocket. In the United States, coverage policies determine which patients qualify for a stimulator trial, how many ablation procedures are allowed per year and whether a non-opioid treatment receives separate payment in an outpatient setting, which the NOPAIN Act now provides for qualifying products. Prior authorisation adds administrative delay and denials. In Europe, national systems set their own criteria, and some restrict implants to specialist centres and specific indications. In emerging markets, patients often pay directly, which favours lower-cost therapies such as ablation and simple devices. The model therefore forecasts therapy mix by region according to payment rules rather than clinical guidelines alone.

Why is the shift to ambulatory settings significant?

The shift of procedures from hospitals to ambulatory surgery centres and office-based practices is significant because it lowers costs, increases capacity and changes who buys devices. Stimulator trials, ablation and injections are increasingly performed in ambulatory centres, where physicians often have ownership stakes and are sensitive to device cost, and where payment rules differ from hospital outpatient departments. The NOPAIN Act’s separate payment applies in both hospital outpatient departments and ambulatory surgery centres, which supports the shift. For manufacturers, this means selling to a more fragmented customer base with sharper price sensitivity, but also reaching more patients as capacity expands. The model links procedure growth partly to ambulatory capacity, particularly in the United States.

Douglas Exclusive: the non-opioid reimbursement and therapy-adoption tracker

This report tracks NOPAIN-qualifying products, payer coverage decisions and procedure volumes by therapy, and links them to demand forecasts. Licence holders receive it as a maintained tab in the Excel model.

The tracker lists products qualifying for separate non-opioid payment and the payment amounts, coverage policies for spinal cord stimulation, peripheral nerve stimulation and ablation by major payer, prior-authorisation requirements, and procedure volumes by setting. It also records new clinical trial results and health technology assessments, since these often precede coverage changes by a year or more. Manufacturers can use it to prioritise indications and markets, and investors to judge whether a company’s growth depends on reimbursement decisions still to come.

How large is the opioid-sparing opportunity?

The opioid-sparing opportunity is large because tens of millions of surgical procedures are performed each year in the United States and Europe alone, and post-surgical prescribing has historically been a route into long-term opioid use for some patients. If even a modest share of those procedures used nerve blocks with catheters, peripheral nerve stimulation, ablation or non-opioid infusions instead of, or alongside, opioids, device volumes would rise substantially. Health systems have adopted enhanced recovery protocols that emphasise multimodal pain control, and professional societies recommend limiting opioid prescriptions. The obstacles are cost, procedure time and clinician training, which is precisely why separate payment for qualifying non-opioid treatments matters. The model treats post-surgical pain as the largest single source of incremental device volume over the forecast, concentrated in ambulatory surgery.

That opportunity is also why several large device companies have acquired or partnered with pain-technology specialists in recent years, and why the competitive chapter tracks pipeline products aimed at post-surgical and neuropathic pain, where the combination of clinical need and payment support is strongest.

Readers should note that this market is unusually sensitive to a small number of policy decisions: a coverage change by one large payer, or an expansion of separate payment rules to more settings, can move procedure volumes more than any product launch.

The scenarios above are built around exactly those variables, which is why the range between them is wide relative to the size of the market today.

Methodology and receipts

The model is built bottom-up from procedures and units by device and region, priced at realised values, with drugs excluded. Every figure carries a numbered source and confidence grade, and the working model ships with every licence. The full method follows the published Douglas Insights methodology. The next scheduled review is September 2027.